Abcam PLC (ABCM)

NASDAQ: ABCM · IEX Real-Time Price · USD
15.52
+0.01 (0.06%)
Dec 9, 2022 4:00 PM EST - Market closed
0.06%
Market Cap 3.56B
Revenue (ttm) 427.32M
Net Income (ttm) 41.10M
Shares Out 228.88M
EPS (ttm) 0.08
PE Ratio 194.00
Forward PE 31.85
Dividend n/a
Ex-Dividend Date n/a
Volume 796,674
Open 15.38
Previous Close 15.51
Day's Range 14.89 - 15.56
52-Week Range 12.54 - 24
Beta 0.46
Analysts Buy
Price Target 20.23 (+30.3%)
Earnings Date Sep 12, 2022

About ABCM

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and rese... [Read more]

Industry Biotechnology
IPO Date Oct 22, 2020
CEO Murray Hennessy
Employees 1,682
Stock Exchange NASDAQ
Ticker Symbol ABCM
Full Company Profile

Financial Performance

In 2021, Abcam's revenue was 315.40 million, an increase of 21.31% compared to the previous year's 260.00 million. Earnings were 4.40 million, a decrease of -64.80%.

Financial numbers in GBP Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for ABCM stock is "Buy." The 12-month stock price forecast is 20.23, which is an increase of 30.35% from the latest price.

Price Target
$20.23
(30.35% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Is Abcam the Perfect Nasdaq Stock?

Abcam PLC ( ABCM , Financial) is a $3.8 billion market cap biotechnology stock on the Nasdaq Global Select Market. It is moving its primary listing from London's AIM (previously known as the Alternative...

3 weeks ago - GuruFocus

ABCAM PLC: Result of General Meeting - Shareholders approve AIM Delisting

CAMBRIDGE, England and WALTHAM, Mass. , Nov. 11, 2022 /PRNewswire/ -- Abcam plc (AIM: ABCM) (ABC: ABCM) (Nasdaq: ABCM) ("Abcam" or the "Company"), a global leader in the supply of life science research ...

4 weeks ago - PRNewsWire

NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research

SEATTLE & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)-- #spatialbiology--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, a...

Other symbols: NSTG
1 month ago - Business Wire

ABCAM PLC: Proposed resolution for cancellation of AIM listing

Proposed Cancellation of Admission of Ordinary Shares to Trading on AIM and Notice of General Meeting Notice of General Meeting to be held on 11 November 2022    NOT FOR RELEASE, PUBLICATION OR DISTRIBU...

1 month ago - PRNewsWire

ABCAM PLC: Interim results for the six-month period ended 30 June 2022

20% constant exchange rate revenue growth in H1: Demand for Abcam In-house Products Increases CAMBRIDGE, England and WALTHAM, Mass. , Sept. 12, 2022 /PRNewswire/ -- Abcam plc (NASDAQ: ABCM) (AIM: ABC) (...

2 months ago - PRNewsWire

ABCAM PLC First Half Trading Update

CAMBRIDGE, England , July 20, 2022 /PRNewswire/ -- Abcam plc ("Abcam", "Company", "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the fol...

4 months ago - PRNewsWire

Abcam: Appointment of Vice President of Investor Relations

CAMBRIDGE, England , June 27, 2022 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces the ap...

5 months ago - PRNewsWire

Abcam the most awarded company at 2022 industry awards

CAMBRIDGE, England, March 25, 2022 /PRNewswire/ --  Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any ...

8 months ago - PRNewsWire

Wall Street Analysts Predict a 27% Upside in Abcam PLC Sponsored ADR (ABCM): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Abcam PLC Sponsored ADR (ABCM). While the effectiveness of this highly sought-after metric is questionab...

8 months ago - Zacks Investment Research

Abcam Plc Results for the 12- and 18-month periods ended 31 December 2021

Growing demand for Abcam's portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates

8 months ago - GlobeNewsWire

Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications

CAMBRIDGE, England & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA ...

Other symbols: TWST
10 months ago - Business Wire

Alamar Biosciences partners with Abcam to drive understanding of the human proteome

FREMONT, Calif. and CAMBRIDGE, England, Jan. 4, 2022 /PRNewswire/ -- Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of canc...

11 months ago - PRNewsWire

Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome

SEATTLE and CAMBRIDGE, England, Nov. 2, 2021 /PRNewswire/ -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying ...

Other symbols: NAUT
1 year ago - PRNewsWire

Abcam completes $340m strategic acquisition and expands kit capacity and capability

- Completing $340m strategic acquisition of BioVision - Expanding facilities in Eugene, further growing kits and assays portfolio - Supporting the growing demand of the sector and accelerating execution...

1 year ago - PRNewsWire

4 High Financial Strength Stocks Trading Near Historical Low Price-Book Ratios

According to the Historical Low Price-Book Screen, a Premium feature of GuruFocus, four stocks with high financial strength and are trading near historical low price-book ratios are Landstar System Inc....

Other symbols: JOBSLSTRSAP
1 year ago - GuruFocus

29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually Recovers and Demand for Abcam In-house Products ...

CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, to...

1 year ago - GlobeNewsWire

Abcam To Acquire Supplier BioVision For $340M In Cash

Abcam plc (NASDAQ: ABCM) has agreed to acquire BioVision Inc, a wholly-owned Boai NKY Medical Holdings Ltd subsidiary, for $340 million in cash. The Milpitas, California-based BioVision is a distributor...

1 year ago - Benzinga

Abcam to Acquire BioVision for $340 million

CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM LSE: ABC; Nasdaq: ABCM) ("Abcam", “the Company” or "the Group"), a global leader in the supply of life science research tools,...

1 year ago - GlobeNewsWire

Abcam opens new US facility in Boston, MA

CAMBRIDGE, July 13, 2021 /PRNewswire/ -- Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences reagents and tools, today announces the opening of a major new site in Waltham, MA.  The new...

1 year ago - PRNewsWire

Pionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients

SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, England, June 22, 2021 /PRNewswire/ -- Today Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body'...

1 year ago - PRNewsWire

2 of the Safest Biotech Stocks You'll Find Today

They provide the infrastructure and sell the tools that biomedical researchers need to make breakthroughs.

Other symbols: ARE
1 year ago - The Motley Fool

Abcam and MEDx extend precision medicine strategic partnership

CAMBRIDGE, United Kingdom and SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDx Translational Medicine (...

1 year ago - GlobeNewsWire

Avacta Announces Distribution Agreement With ABCAM plc

CAMBRIDGE, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to...

1 year ago - Business Wire

5 Companies Trading Below Historical Low Price-Book as of March

Stocks with high business profitability and price-book ratios near 10-year lows

Other symbols: ATHMHSTMJOBSSAP
1 year ago - GuruFocus

Abcam Wins Industry Awards from CiteAb

CAMBRIDGE, United Kingdom, March 24, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced that Dr Alejandra Solache, SVP of Resea...

1 year ago - GlobeNewsWire